We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/3/2021 15:48 | .. and it's not down to Finncap, because SNG and others seem to have done just fine with them. | on target | |
11/3/2021 15:44 | Yep, and Evolution weren’t the whitest of white when it came to stock braking, market making etc..! | bumpa33 | |
11/3/2021 15:34 | That is interesting, Bumpa. I did not know that about RG. Anyway, I am pleased that Octopus came on board, a name that I also have a lot of respect for. GLA. | lovewinshatelosses | |
11/3/2021 15:20 | Diluted yes, rather depends on how the cash is utilized though no? We’re priced with almost zero regard to potential. So you either see a mad pricing anomaly or you agree that this has zero potential. It is a frustrating wait I’ll grant you. | bumpa33 | |
11/3/2021 15:16 | mesquida - it is what it is with Finncap. If you can name me a better broker (morals, integrity etc etc) at the lower end of the food chain, I’d be amazed. | bumpa33 | |
11/3/2021 14:41 | LOL so the tale of intrigue gets even more intriguing. So let's recap. Huw had a zoom call with nico115 and told him he wanted £3m. But then Finncap decided to play a nasty trick on Huw and went and raised £10m instead! What a jolly jape. Then poor Huw had to quickly make up all that stuff about how he would spend the £10m. Have I got this right? | on target | |
11/3/2021 13:19 | Lwhl - Griffith was founder of long departed Evolution - bought out by Investec many moons ago - he’s a trader by nature. He’s had his share of success and failures over the years, but then ain’t we all. | bumpa33 | |
11/3/2021 13:12 | Nico turning up on this BB is the biggest negative that I see also! | brasso3 | |
11/3/2021 13:07 | I can find one negative moneymunch - nico says he has 2 million shares in Evgen, that he is considering selling. Or has he changed his mind? :-) | clocktower | |
11/3/2021 13:03 | It's hard to find many negatives with so much cash in the bank with so many shots on multiple targets, the oversubscribed £11m fund raise speaks volumes imho, and suggests that the new high quality sharholders such as Octopus must be highly confident of Evgen's prospects and potential going forward, and more disclosures to come in the coming days. Evgen now has c£13m cash which is a subtantial amount commensurate to their current value, and allows Huw and the team to accelerate development of the pipeline and grow the company for the next couple of years, which offers a very exciting risk/reward opportunity and tremendous upside potential on success, for all invested. Gla ;-) | moneymunch | |
11/3/2021 12:24 | It is what it is I was on the zoom so I heard first hand how much money they were looking to raise | nico115 | |
11/3/2021 11:45 | Yes, first hurdle clear and as you say Bumpa, nothing unexpected, so no surprises to see little movement in the share price today. Was nervous before I opened the RNS though. Nice to have a clear indication of when we will get the news that will either light the touch paper, or cause discomfort, from the reviewed data of this trial. Hopefully we will enjoy a nice rise as we approach that period. While I would have also liked to see RG increase his position here, I remember him dumping stock in other shares that went on to rocket shortly afterwards, so while he is clearly an impressive investor, he does not always get it right! I certainly hope he is wrong here :) A part of me also hopes he is wrong with his increased holding of C4X, which I mentioned being tied up here at the time meant I did not have the cash available to invest there, when the share price was something like 16p. Laugh and the whole world laughs with you - apparently! GLA. | lovewinshatelosses | |
11/3/2021 11:04 | There's no need for recollections here, we have RNSs. Unless nico reckons he heard Huw talking about raising £3m (or was it £5m like he said in his first post) down the pub? | on target | |
11/3/2021 10:42 | As the Queen has suggest about Meghan's comments - On Target - Different recollections | clocktower | |
11/3/2021 10:16 | Says it like it is, apart from making up stuff about the placing. | on target | |
11/3/2021 10:10 | Say it like it is nico115. Nice positive sounds from you today - "Limited downside now" If that's not a buy signal from you, what is. :-) | clocktower | |
11/3/2021 08:13 | good news on safety, though not unexpected. The next one is the big one. | bumpa33 | |
11/3/2021 07:43 | Positive interim efficacy data on SFX-01 for Covid/Ards from Prof Chalmers will be a complete game changer, undoubted transformational upside potential on multiple fronts and fully funded for the forseeable......a very attractive risk/reward opportunity from this current rock bottom low. Gla ;-) | moneymunch | |
11/3/2021 07:41 | After my earlier pessimism, I received 70% of my excess (27913/40000), which is more than I expected. | ewanwhose | |
11/3/2021 07:34 | Good rns today Limited downside now Let's agree to disagree about director buys as free bet for them which is wrong | nico115 | |
11/3/2021 07:20 | Prof Chalmers, Lead investigator for SFX-01 Covid/ARDS patient trials, is on the organisation committee for the following event, and so every chance that he could be reporting good news on SFX-01's efficacy for Covid/Ards 29th April 2021.Gla ;-) COVID-19: State of the art – DRAGON IMI project 29 April, 2021 Online A full-day virtual event dedicated to COVID-19, where top level faculty will share the latest advances, data and best practices relating to SARS-CoV-2 and COVID-19. “This event brings together world-leaders tackling COVD-19 and how different digital approaches to big data will help us to defeat the pandemic” – Professor Christopher Brightling, event co-chair. | moneymunch |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions